News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Aref Al-Kali: New concept and potential biological subgroup for relapsed or refractory AML
Photo of Aref Al-Kali from mayoclinic.org
Feb 2, 2025, 01:37

Aref Al-Kali: New concept and potential biological subgroup for relapsed or refractory AML

Aref Al-Kali, Hematologist/Oncologist at Mayo Clinic, shared a post on X, adding:

“I mentioned this abstract a year ago. Now published in Blood Journal.

New concept and potential biological subgroup -RUNX1- that benefit the most.”

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia

Authors: Yuchen Liu et al.

Aref Al-Kali: New concept and potential biological subgroup for relapsed or refractory AML

Quoting his original post:

“PegC plus VEN in patients with rrAML has activity esp in RUNX1m. Excellent work and new front on targeting oncometabolome.”

Aref Al-Kali: New concept and potential biological subgroup for relapsed or refractory AML

Ashkan Emadi Christine C. Dougherty Dominique R. Bollino Erin T. Strovel Farin Kamangar Jan H. Beumer Jinoos Zarrabi Katherine D. Caprinolo Maria R. Baer Osman M. Bah Rena G. Lapidus Sandrine Niyongere Sunita Philip Tien V. Le Vu H. Duong Yuchen Liu
Special Coverage
Blog
Feb 2, 2025, 01:37
Aref Al-Kali: New concept and potential biological subgroup for relapsed or refractory AML
Insight
Feb 2, 2025, 01:35
Anna Berkenblit: Key pancreatic cancer research updates from ASCO GI25
Insight
Feb 2, 2025, 01:32
Chiara Mercinelli: Honored to receive the Best Publication in Urological Oncology award
Blog
Feb 2, 2025, 00:59
The benefits and challenges of cancer registries in global cancer care - The Lancet
Blog
Feb 2, 2025, 00:57
Patient-Reported Incidence of Fatigue During Palbociclib and Endocrine Therapy in Advanced HR+ HER2- Breast Cancer
Insight
Feb 2, 2025, 00:54
Chad Tang: Optimizing breath-hold continuous motion gating for kidney cancer
Blog
Feb 2, 2025, 00:52
Stephen V Liu: Will G12D inhibitors emerge or pan KRAS or pan RAS?
Blog
Feb 1, 2025, 19:23
Mohit Manrao: Incredible work around the globe in oncology
Blog
Feb 1, 2025, 19:21
E. Anders Kolb rang the Nasdaq opening bell on behalf of all blood cancer patients and their families
Blog
Feb 1, 2025, 19:03
Noelene Kotschan: Closing the Cancer Care Gap in Soweto South Africa
Blog
Feb 1, 2025, 19:01
Dégi László Csaba: Discussions on the future of cancer care at the World Economic Forum in 2025
Blog
Feb 1, 2025, 18:59
Shan Li O'Connor: An incredible milestone in my career